1. The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease.
- Author
-
Jorgačević B, Vučević D, Đuričić I, Šobajić S, Mladenović D, Vesković M, Vukićević RJ, and Radosavljević T
- Subjects
- Administration, Oral, Animals, Cannabinoid Receptor Antagonists administration & dosage, Diet, High-Fat, Male, Mice, Mice, Inbred C57BL, Non-alcoholic Fatty Liver Disease chemically induced, Non-alcoholic Fatty Liver Disease drug therapy, Piperidines administration & dosage, Pyrazoles administration & dosage, Receptor, Cannabinoid, CB2 metabolism, Rimonabant, Cannabinoid Receptor Antagonists pharmacology, Fatty Acids, Nonesterified metabolism, Liver drug effects, Liver metabolism, Non-alcoholic Fatty Liver Disease metabolism, Piperidines pharmacology, Pyrazoles pharmacology, Receptor, Cannabinoid, CB2 antagonists & inhibitors
- Abstract
We used rimonabant to investigate the role of CB1 receptor on hepatic FFAs profile during NAFLD. Male mice C57BL/6 were divided into: control group fed with control diet 20 weeks (C; n=6); group fed with HFD 20 weeks (HF; n=6); group fed with control diet and treated with rimonabant after 18 weeks (R; n=9); group fed with HFD and treated with rimonabant after 18 weeks (HFR; n=10). Rimonabant (10mg/kg) was administered daily to HFR and R group by oral gavage. Rimonabant decreased liver palmitic acid proportion in HFR group compared to HF group (p<0.05). Liver stearic and oleic acid proportions were decreased in R group compared to control (p<0.01 respectively). Rimonabant increased liver linoleic and arachidonic acid proportions in HFR group compared to HF group (p<0.01 respectively). CB1 blockade may be useful in the treatment of HFD-induced NAFLD due to modulation of plasma lipid and hepatic FFA profile., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF